Skip to main content
AAN.com
Articles
March 24, 2008

Patterns and stages of α-synucleinopathy
Relevance in a population-based cohort

J. Zaccai, PhD, C. Brayne, PhD, I. McKeith, MD, F. Matthews, PhD, P. G. Ince, MD, and On behalf of the MRC Cognitive Function, Ageing Neuropathology StudyAuthors Info & Affiliations
March 25, 2008 issue
70 (13) 1042-1048

Abstract

Background: It is proposed that α-synucleinopathy (AS) initially affects the medulla oblongata and progresses to more rostral brain areas in a hierarchical sequence (“Braak hypothesis”). Predominant involvement of the amygdala is also described. This study examines the applicability of these patterns, and their relationship to Alzheimer disease (AD) pathology, in brains of a population-based donor cohort.
Methods: Brains donated in two of six Cognitive Function and Ageing Study cohorts (Cambridgeshire and Nottingham) were examined. More than 80% were older than 80 years at death. The respondents were evaluated prospectively in life for cognitive decline and dementia. Immunocytochemistry for tau and α-synuclein was carried out in 208 brains to establish Braak stage and the pattern and severity of AS.
Results: Seventy-six brains showed Lewy bodies. Half (51%) conformed to the Braak hypothesis while 17% had pathology in a higher region which was absent in a lower region. A further 29% showed amygdala-predominant pathology. Six brains showed predominant neocortical pathology with minimal pathology in amygdala or substantia nigra. The stage of AD pathology was not associated with particular patterns of AS.
Conclusion: α-Synucleinopathy (AS) is common in older people, and frequently associated with Alzheimer disease–type pathology. Although half of brains corresponded to the Braak hypothesis, and 29% to amygdala-predominant AS, there were a high proportion of cases which did not fit a staging system. An unexpectedly high proportion with a cortical form of Lewy body disease was identified.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.doc)
File (e2.doc)
File (e3.doc)

REFERENCES

1.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479–486.
2.
Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–278; discussion 278–284.
3.
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
4.
MRC-CFAS. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169–175.
5.
Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol (Berl) 2003;106:374–382.
6.
Perry RH, Irving D, Tomlinson BE. Lewy body prevalence in the aging brain: relationship to neuropsychiatric disorders, Alzheimer-type pathology and catecholaminergic nuclei. J Neurol Sci. 1990;100:223–233.
7.
Ince PG, McArthur FK, Bjertness E, Torvik A, Candy JM, Edwardson JA. Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions. Dementia 1995;6:162–168.
8.
Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378–384.
9.
Parkkinen L, Soininen H, Laakso M, Alafuzoff I. Alpha-synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001;27:314–325.
10.
Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 2005;57:82–91.
11.
Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000;57:1145–1150.
12.
Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413–426.
13.
Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88:493–500.
14.
Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153–159.
15.
Saito Y, Kawashima A, Ruberu NN, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003;62:644–654.
16.
Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 2004;61:1915–1919.
17.
Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006;65:685–697.
18.
Kosaka K. [Diffuse Lewy body disease]. Rinsho Shinkeigaku 1995;35:1455–1456.
19.
Brayne C. Clinicopathological studies of the dementias from an epidemiological viewpoint. Br J Psychiatry 1993;162:439–446.
20.
Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of dementia: design, methods and areas of investigation: a systematic review. BMC Neurol 2006;6:2.
21.
MRC-CFAS. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol Med 1998;28:319–335.
22.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
23.
Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med 1986;16:89–99.
24.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
25.
van Belle G, Gibson K, Nochlin D, Sumi M, Larson EB. Counting plaques and tangles in Alzheimer's disease: concordance of technicians and pathologists. J Neurol Sci 1997;145:141–146.
26.
Lopez OL, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53:1292–1299.
27.
Chui HC, Tierney M, Zarow C, Lewis A, Sobel E, Perlmutter LS. Neuropathologic diagnosis of Alzheimer disease: interrater reliability in the assessment of senile plaques and neurofibrillary tangles. Alzheimer Dis Assoc Disord 1993;7:48–54.
28.
Crystal HA, Dickson DW, Lizardi JE, Davies P, Wolfson LI. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523–1528.
29.
Galasko D, Hansen LA, Katzman R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994;51:888–895.
30.
McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324–332.
31.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745–752.
32.
Cercy SP, Bylsma FW. Lewy bodies and progressive dementia: a critical review and meta-analysis. J Int Neuropsychol Soc 1997;3:179–194.
33.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863–1872.
34.
Yamamoto R, Iseki E, Marui W, et al. Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 2005;25:188–194.
35.
Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45–50.
36.
Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G, Katayama Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res 2001;888:287–296.
37.
Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol 2003;62:363–367.
38.
Trembath Y, Rosenberg C, Ervin JF, et al. Lewy body pathology is a frequent co-pathology in familial Alzheimer's disease. Acta Neuropathol (Berl) 2003;105:484–488.
39.
Gomez-Tortosa E, Irizarry MC, Gomez-Isla T, Hyman BT. Clinical and neuropathological correlates of dementia with Lewy bodies. Ann NY Acad Sci 2000;920:9–15.

Information & Authors

Information

Published In

Neurology®
Volume 70Number 13March 25, 2008
Pages: 1042-1048
PubMed: 18362284

Publication History

Published online: March 24, 2008
Published in print: March 25, 2008

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

J. Zaccai, PhD
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.
C. Brayne, PhD
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.
I. McKeith, MD
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.
F. Matthews, PhD
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.
P. G. Ince, MD
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.
On behalf of the MRC Cognitive Function, Ageing Neuropathology Study
From Institute of Public Health (J.Z., C.B.), University of Cambridge; Institute for Ageing and Health (I.M.), University of Newcastle upon Tyne; MRC Biostatistics Unit (F.M.); and Section of Neurosciences (P.G.I.), University of Sheffield, UK.

Notes

Address correspondence and reprint requests to Professor Paul G. Ince, Neuropathology, E Floor, Royal Hallamshire Hospital, Sheffield UK, S10 2JF [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Mediterranean Diet Adherence, Gut Microbiota and Parkinson’s Disease: A Systematic Review, Nutrients, 16, 14, (2181), (2024).https://doi.org/10.3390/nu16142181
    Crossref
  2. The Role of Astrocytes and Alpha-Synuclein in Parkinson’s Disease: A Review, NeuroSci, 5, 1, (71-86), (2024).https://doi.org/10.3390/neurosci5010005
    Crossref
  3. Navigating the Neurobiology of Parkinson’s: The Impact and Potential of α-Synuclein, Biomedicines, 12, 9, (2121), (2024).https://doi.org/10.3390/biomedicines12092121
    Crossref
  4. Inflammation and heterogeneity in synucleinopathies, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1432342
    Crossref
  5. Sex Differences in Dementia, Cognition, and Health in the Cognitive Function and Ageing Studies (CFAS), Journal of Alzheimer's Disease, 100, s1, (S3-S12), (2024).https://doi.org/10.3233/JAD-240358
    Crossref
  6. Extracellular vesicles contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology, Biochemical and Biophysical Research Communications, 703, (149620), (2024).https://doi.org/10.1016/j.bbrc.2024.149620
    Crossref
  7. Enhanced Spine Stability and Survival Lead to Increases in Dendritic Spine Density as an Early Response to Local Alpha-Synuclein Overexpression in Mouse Prefrontal Cortex, Cellular and Molecular Neurobiology, 44, 1, (2024).https://doi.org/10.1007/s10571-024-01472-7
    Crossref
  8. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden, Acta Neuropathologica, 147, 1, (2024).https://doi.org/10.1007/s00401-023-02663-0
    Crossref
  9. Spatial-temporal dynamic evolution of lewy body dementia by metabolic PET imaging, European Journal of Nuclear Medicine and Molecular Imaging, (2024).https://doi.org/10.1007/s00259-024-06881-w
    Crossref
  10. Conjugal Synucleinopathies: A Clinicopathologic Study, Movement Disorders, 39, 7, (1212-1217), (2024).https://doi.org/10.1002/mds.29783
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share